Metagenomi Therapeutics (MGX) Change in Account Payables (2023 - 2026)
Metagenomi Therapeutics (MGX) reported Change in Account Payables of $795000.0 for Q1 2026, down 64.03% year-over-year from $2.2 million in Q1 2025, and up 129.77% quarter-over-quarter from $346000.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Change in Account Payables (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 4 years of Change in Account Payables data on file, last reported at $795000.0 in Q1 2026.
- Change in Account Payables for Q1 2026 came in at $795000.0, down 64.03% year-over-year; the trailing twelve-month figure through Mar 2026 was -$361000.0 (up 82.43% YoY), and the FY2025 annual result was $1.1 million, up 195.3% from the prior year.
- Change in Account Payables climbed to $795000.0 in Q1 2026 per MGX's latest filing, from $346000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $3.2 million in Q1 2024 and troughed at -$2.6 million in Q4 2024.
- A 4-year average of $50692.3 and a median of $74000.0 in 2025 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2024 and 2025: Change in Account Payables surged 162.16% in 2024, then slumped 483.7% in 2025.
- A 4-year view of Change in Account Payables shows it stood at -$2.5 million in 2023, then declined by 1.86% to -$2.6 million in 2024, then surged by 113.46% to $346000.0 in 2025, then jumped by 129.77% to $795000.0 in 2026.
- Business Quant data shows MGX's Change in Account Payables at $795000.0 in Q1 2026, $346000.0 in Q4 2025, and -$1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | -9.42 Mn |
| 10 | Metagenomi Therapeutics | 42.84 Mn | 42.84 Mn | - | 795,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 795,000.00 |
| Mar 31, 2026 | 795,000.00 |
| Dec 31, 2025 | 346,000.00 |
| Dec 31, 2025 | 346,000.00 |
| Sep 30, 2025 | -1.58 Mn |
| Sep 30, 2025 | -1.58 Mn |
| Jun 30, 2025 | 74,000.00 |
| Jun 30, 2025 | 74,000.00 |
| Mar 31, 2025 | 2.21 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Dec 31, 2024 | -2.57 Mn |
| Dec 31, 2024 | -2.57 Mn |
| Sep 30, 2024 | -270,000.00 |
| Sep 30, 2024 | -270,000.00 |
| Jun 30, 2024 | -1.43 Mn |
| Jun 30, 2024 | -1.43 Mn |
| Mar 31, 2024 | 3.16 Mn |
| Mar 31, 2024 | 3.16 Mn |
| Dec 31, 2023 | -2.52 Mn |
| Dec 31, 2023 | -2.52 Mn |